Astellas Pharma Inc.

4503

JP3942400007

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-17 am EDT			5-day change	1st Jan Change
1,487 ^JPY	-1.75%		-2.65%	-11.80%

May. 16	Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	DJ
May. 08	Astellas Unveils New, State-Of-The-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor	CI

Astellas Pharma Inc. Provides Consolidated Earnings Guidance on Full Basis for the Full-Year 2024

April 25, 2024 at 02:00 am EDT

Astellas Pharma Inc. provided consolidated earnings guidance on full basis for the full-year 2024. For the year, the company expected revenue of JPY 1,650,000 million, Core operating profit of JPY 250,000 million, Core profit for the year of JPY 186,000 million and Basic core earnings per share of JPY 103.73.

Latest news about Astellas Pharma Inc.

Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	May. 16	DJ
Astellas Unveils New, State-Of-The-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor	May. 08	CI
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos	May. 02	MT
Malin Corp investee signs agreement with Astellas Pharma	May. 01	AN
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences	May. 01	DJ
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	Apr. 30	RE
Transcript : Astellas Pharma Inc., 2024 Earnings Call, Apr 25, 2024	Apr. 25
Astellas Pharma Inc. Declares Year End Dividend for the Year Ended March 31, 2023 and Provides Interim and Year End Dividend Guidance for the Fiscal Year 2024	Apr. 25	CI
Astellas Pharma Inc. Provides Consolidated Earnings Guidance on Full Basis for the Full-Year 2024	Apr. 25	CI
Astellas Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	Apr. 25	CI
Astellas Pharma Inc. Announces Board and Committee Retirements	Apr. 25	CI
European Commission Approves Astellas Pharma Label Extension for Xtandi	Apr. 24	MT
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting	Apr. 23	CI
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	Apr. 22	MT
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	Apr. 22	CI
Lupin Launches Mirabegron Extended-Release Tablets in US	Apr. 21	MT
Japan Inc makes a renewed U.S. push as China fears mount	Apr. 17	RE
Middle East Tensions Blunt Asian Stock Markets Excepting China	Apr. 15	MT
Astellas Pharma Cuts Attributable Profit Forecast for Fiscal Year Ended March	Apr. 15	MT
Japan's Nikkei sags as Iran attack, Wall Street sell-off sour sentiment	Apr. 15	RE
Japan's Nikkei drops 1% as Iran attack, Wall Street sell-off fuel risk aversion	Apr. 14	RE
Astellas Pharma Inc. Provides Impairment Loss for Intangible Assets Guidance for the Fourth Quarter 2023	Apr. 12	CI
Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	Apr. 12	CI
Jefferies Adjusts Astellas Pharma’s Price Target to 2,100 Yen From 2,200 Yen, Keeps at Buy	Apr. 03	MT
U.S. FDA Accepts Astellas? Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy	Mar. 31	CI

Chart Astellas Pharma Inc.

Duration

Period

More charts

Company Profile

Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).

Sector

Pharmaceuticals

Calendar

2024-05-30 - American Society of Clinical Oncology Annual Meeting - Abstract Number : e23287

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Astellas Pharma Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,487 JPY

Average target price

1,991 JPY

Spread / Average Target

+33.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTELLAS PHARMA INC.	-11.80%	17.15B
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals